Information for Healthcare Professionals | LUCENTIS® (ranibizumab injection)

Search Preview

Information for Healthcare Professionals | LUCENTIS® (ranibizumab ...

www.eyeonvegfa.org/

Find important information about LUCENTIS® (ranibizumab injection) specifically tailored for healthcare professionals here. INDICATIONS LUCENTIS® ( ...

Most Used Html Elements

<div> : 174
<p> : 53
<a> : 46
<i> : 39
<span> : 33
<source> : 33
<li> : 21
<dd> : 18
<dt> : 18
<script> : 14
<picture> : 11
<img> : 11
<ul> : 8
<sup> : 7
<section> : 7
<br> : 6
<b> : 5
<meta> : 5
<link> : 5
<h6> : 5
<h5> : 4
<footer> : 3
<header> : 3
<h4> : 3

Most Used Html Classes

"section" : 26
"cq-dd-paragraph" : 15
"snippet" : 15
"imsafe-distribution-..." : 15
"ignore-glossary" : 15
"safety-reference-cal..." : 15
"safety-reference-cal..." : 15
"fa" : 13
"gene-component--call..." : 12
"gene-component--navi..." : 11
"gene-component--navi..." : 11
"gene-component--imag..." : 11
"gene-component--imag..." : 11
"exclude-from-glossar..." : 11
"gene-component--imag..." : 10
"gene-component--butt..." : 8
"gene-component--butt..." : 8
"gene-component--navi..." : 6
"gene-component--imag..." : 6
"gene-component--navi..." : 6
"gene-template__conta..." : 6
"gene-component--link..." : 6
"gene-component--link..." : 6
"gene-component--navi..." : 5
"gene-template__colum..." : 5
"gene-template__colum..." : 5
"gene-component--navi..." : 5
"gene-template__autho..." : 5
"gene-component--navi..." : 5
"fa-chevron-circle-ri..." : 4
"gene-component--call..." : 4
"gene-component--butt..." : 4
"gene-component--refe..." : 4
"gene-component--call..." : 4
"gene-component--call..." : 4
"gene-component--call..." : 4
"gene-component--audi..." : 4
"gene-component--call..." : 4
"gene-component--moda..." : 4
"gene-component--butt..." : 4
"gene-component--call..." : 4
"gene-template__callo..." : 4
"gene-component--butt..." : 4
"gene-component--audi..." : 4
"callout" : 4
"gene-component--audi..." : 4
"page" : 4
"gene-component--call..." : 4
"gene-component--audi..." : 4
"gene-component--link..." : 3
"fa-chevron-down" : 3
"gene-component--head..." : 3
"parsys" : 3
"gene-template__conte..." : 3
"gene-component--head..." : 3
"iparsys" : 3
"iparys_inherited" : 3
"image" : 2
"image-v2" : 2
"gene-component--navi..." : 2
"gene-component--navi..." : 2
"gene-component--navi..." : 2
"gene-component--navi..." : 2
"gene-component--moda..." : 2
"gene-component--moda..." : 2
"gene-component--moda..." : 2
"gene-component--audi..." : 2
"gene-component--head..." : 2
"gene-component--safe..." : 2
"gene-component--safe..." : 2
"gene-component--pi-b..." : 2
"gene-component--head..." : 2
"gene-component--pi-b..." : 2
"gene-component--audi..." : 2
"gene-component--moda..." : 2
"gene-component--moda..." : 2
"gene-component--moda..." : 2
"new" : 2
"gene-component--moda..." : 2
"gene-component--moda..." : 2
"gene-component--audi..." : 2
"sr-only" : 2
"gene-component--audi..." : 2
"gene-component--audi..." : 2
"fa-times" : 2

Where is www.eyeonvegfa.org hosted?

Country:

United States

Registrar:

Public Interest Registry

Latitude:

34.05

Longitude:

-118.24

IP address:

72.34.128.178

IP Binary address:

1001000001000101000000010110010

IP Octal address:

11010500262

IP Hexadecimal address:

482280b2

Context analysis of eyeonvegfa.org

Number of letters on this page:

4 308

Number of words on this page:

963

Number of sentences on this page:

52

Average words per sentences on this page:

19

Number of syllables on this page:

1 444

Number of Bold texts:

5

Number of Italic texts:

26

Domain name architecture

Domain name length:

14

Hyphens:

Domain doesn't contain hyphens!

Domain name with Hindi letters:

ए ग़ ए ओ ञ व ए ग फ़ अ . ओ र ग

Domain name with Hebrew letters:

(e) י (e) (ο) נ ו (e) ג ף (a) . (ο) ר ג

Domain name with Cyrillic letters:

e y e о н в e г φ a . о р г

Domain name with Arabic letters:

(e) ي (e) (o) ن (v) (e) غ ف ا . (o) ر غ

Domain name with Greek letters:

ε y ε ο ν (v) ε γ φ α . ο ρ γ

Domain name with Chinese letters:

伊吾艾伊哦艾娜维伊吉艾弗诶 . 哦艾儿吉

Domain without Consonants:

ynvgf.rg

Domain without Vowels:

eyeoea.o

Alphabet positions:

e⁵ y²⁵ e⁵ o¹⁵ n¹⁴ v²² e⁵ g⁷ f⁶ a¹ . o¹⁵ r¹⁸ g⁷

Domain name pattern:
V: Vowel, C: Consonant, N: Number

V C V V C C V C C V . V C C

<HEAD> DATA INFORMATION

Encoding:

utf-8

description:

Find important information about LUCENTIS® (ranibizumab injection) specifically tailored for healthcare professionals here. INDICATIONS LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with: Neovascular (wet) age-related macular degeneration (wAMD) Macular edema following retinal vein occlusion (RVO) Diabetic macular edema (DME) Diabetic retinopathy (DR) Myopic choroidal neovascularization (mCNV) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. WARNINGS AND PRECAUTIONS Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored following the injection to permit early treatment, should an infection occur. Increases in intraocular pressure (IOP) have been noted both pre-injection and post-injection (at 60 minutes) with LUCENTIS. Monitor intraocular pressure prior to and following intravitreal injection with LUCENTIS and manage appropriately. Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). Neovascular (wet) age-related macular degeneration The ATE rate in the 3 controlled neovascular AMD studies during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of LUCENTIS-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the study during the first year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3. In a pooled analysis of 2-year controlled studies (AMD-1, AMD-2, and a study of LUCENTIS used adjunctively with verteporfin photodynamic therapy), the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg LUCENTIS compared to 1.1% (5 of 435) in patients in the control arms (odds ratio 2.2 [95% confidence interval (0.8-7.1)]). Macular edema following retinal vein occlusion The ATE rate in the 2 controlled RVO studies during the first 6 months was 0.8% in both the LUCENTIS and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of LUCENTIS-treated patients compared to 0.4% (1 of 260) in the control arms. Diabetic macular edema and Diabetic Retinopathy In a pooled analysis of Studies DME-1 and DME-2, the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg LUCENTIS, 5.6% (14 of 250) with 0.3 mg LUCENTIS, and 5.2% (13 of 250) with control. The stroke rate at 2 years was 3.2% (8 of 250) with 0.5 mg LUCENTIS, 1.2% (3 of 250) with 0.3 mg LUCENTIS, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg LUCENTIS and 10.8% (27 of 250) with 0.3 mg LUCENTIS; the stroke rate was 4.8% (12 of 249) with 0.5 mg LUCENTIS and 2.0% (5 of 250) with 0.3 mg LUCENTIS. Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. A pooled analysis of Studies D-1 and D-2, showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg LUCENTIS, in 2.8% (7 of 250) of patients treated with 0.3 mg LUCENTIS, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg LUCENTIS and in 4.4% (11 of 250) of patients treated with 0.3 mg LUCENTIS. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded. ADVERSE EVENTS Serious adverse events related to the injection procedure that occurred in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract. In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough. As with all therapeutic proteins, there is the potential for an immune response in patients treated with LUCENTIS. The clinical significance of immunoreactivity to LUCENTIS is unclear at this time. For additional safety information, please see LUCENTIS full Prescribing Information.

viewport:

width=device-width, initial-scale=1

Possible email addresses for eyeonvegfa.org

info@eyeonvegfa.org
email@eyeonvegfa.org
support@eyeonvegfa.org
contact@eyeonvegfa.org
admin@eyeonvegfa.org
postmaster@eyeonvegfa.org
hostmaster@eyeonvegfa.org
domain@eyeonvegfa.org
abuse@eyeonvegfa.org

Possible Domain Typos

www.yeonvegfa.org, www.ewyeonvegfa.org, www.wyeonvegfa.org, www.esyeonvegfa.org, www.syeonvegfa.org, www.edyeonvegfa.org, www.dyeonvegfa.org, www.efyeonvegfa.org, www.fyeonvegfa.org, www.eryeonvegfa.org, www.ryeonvegfa.org, www.e3yeonvegfa.org, www.3yeonvegfa.org, www.e4yeonvegfa.org, www.4yeonvegfa.org, www.eeonvegfa.org, www.eyteonvegfa.org, www.eteonvegfa.org, www.eygeonvegfa.org, www.egeonvegfa.org, www.eyheonvegfa.org, www.eheonvegfa.org, www.eyjeonvegfa.org, www.ejeonvegfa.org, www.eyueonvegfa.org, www.eueonvegfa.org, www.eyonvegfa.org, www.eyewonvegfa.org, www.eywonvegfa.org, www.eyesonvegfa.org, www.eysonvegfa.org, www.eyedonvegfa.org, www.eydonvegfa.org, www.eyefonvegfa.org, www.eyfonvegfa.org, www.eyeronvegfa.org, www.eyronvegfa.org, www.eye3onvegfa.org, www.ey3onvegfa.org, www.eye4onvegfa.org, www.ey4onvegfa.org, www.eyenvegfa.org, www.eyeoinvegfa.org, www.eyeinvegfa.org, www.eyeoknvegfa.org, www.eyeknvegfa.org, www.eyeolnvegfa.org, www.eyelnvegfa.org, www.eyeopnvegfa.org, www.eyepnvegfa.org, www.eyeo9nvegfa.org, www.eye9nvegfa.org, www.eyeo0nvegfa.org, www.eye0nvegfa.org, www.eyeovegfa.org, www.eyeonbvegfa.org, www.eyeobvegfa.org, www.eyeongvegfa.org, www.eyeogvegfa.org, www.eyeonhvegfa.org, www.eyeohvegfa.org, www.eyeonjvegfa.org, www.eyeojvegfa.org, www.eyeonmvegfa.org, www.eyeomvegfa.org, www.eyeon vegfa.org, www.eyeo vegfa.org, www.eyeonegfa.org, www.eyeonvegfa.org, www.eyeonegfa.org, www.eyeonvcegfa.org, www.eyeoncegfa.org, www.eyeonvdegfa.org, www.eyeondegfa.org, www.eyeonvfegfa.org, www.eyeonfegfa.org, www.eyeonvgegfa.org, www.eyeongegfa.org, www.eyeonvbegfa.org, www.eyeonbegfa.org, www.eyeonv egfa.org, www.eyeon egfa.org, www.eyeonvgfa.org, www.eyeonvewgfa.org, www.eyeonvwgfa.org, www.eyeonvesgfa.org, www.eyeonvsgfa.org, www.eyeonvedgfa.org, www.eyeonvdgfa.org, www.eyeonvefgfa.org, www.eyeonvfgfa.org, www.eyeonvergfa.org, www.eyeonvrgfa.org, www.eyeonve3gfa.org, www.eyeonv3gfa.org, www.eyeonve4gfa.org, www.eyeonv4gfa.org, www.eyeonvefa.org, www.eyeonvegrfa.org, www.eyeonverfa.org, www.eyeonvegffa.org, www.eyeonveffa.org, www.eyeonvegvfa.org, www.eyeonvevfa.org, www.eyeonvegtfa.org, www.eyeonvetfa.org, www.eyeonvegbfa.org, www.eyeonvebfa.org, www.eyeonvegyfa.org, www.eyeonveyfa.org, www.eyeonveghfa.org, www.eyeonvehfa.org, www.eyeonvegnfa.org, www.eyeonvenfa.org, www.eyeonvega.org, www.eyeonvegfca.org, www.eyeonvegca.org, www.eyeonvegfda.org, www.eyeonvegda.org, www.eyeonvegfea.org, www.eyeonvegea.org, www.eyeonvegfra.org, www.eyeonvegra.org, www.eyeonvegfta.org, www.eyeonvegta.org, www.eyeonvegfga.org, www.eyeonvegga.org, www.eyeonvegfba.org, www.eyeonvegba.org, www.eyeonvegfva.org, www.eyeonvegva.org, www.eyeonvegf.org, www.eyeonvegfaq.org, www.eyeonvegfq.org, www.eyeonvegfaw.org, www.eyeonvegfw.org, www.eyeonvegfaz.org, www.eyeonvegfz.org, www.eyeonvegfax.org, www.eyeonvegfx.org, www.eyeonvegfas.org, www.eyeonvegfs.org,

More Sites

MrMail - Zimbra Premium E-Mail Provider - Exchange Email Service , Business Email Hosting Solutions, Business Email Package, Business Email Hosting Services, Business Email Hosting, Email Hosting Solutions, Email Hosting Services

MrMail Zimbra Exchange Business Mail Services, kompatibel zu MAC OS, Android, Windows und Linux, die beste und sicherste Lösung für Ihre e-mails - Exchange Email Service , Business Email Hosting Solutions, Business Email Package, Business Email Hosting Services, Business Email Hosting, Email Hosting Solutions, Email Hosting Services

Number of used Technologies: 0
Number of used Javascript files: 0
Server Software: Apache/2.2.31 (Unix) mod_ssl/2.2.31 OpenSSL/1.0.1e-fips mod_bwlimited/1.4
Server Location: Canada / Montréal - 70.38.39.8
List of used Technologies: Google Analytics

Watchman Youth Empowerment Scheme | Inspiring You To Greatness!.

Number of used Technologies: 31
Number of used Javascript files: 31
Server Software: Apache
Server Location: United States / Chicago - 208.117.46.239
List of used Technologies: Wordpress CMS, CSS (Cascading Style Sheets), Font Awesome, Google Font API, Html (HyperText Markup Language), Html5, Javascript, jQuery, Php (Hypertext Preprocessor), Pingback, Revslider, Shortcodes, SVG (Scalable Vector Graphics)

QCPharma - Quality Control For Pharrmacy

Tryptic Soy Broth, Pharmacy Quality Control, USP

Number of used Technologies: 0
Number of used Javascript files: 0
Server Software: Apache/2.0.52 (Red Hat)
Server Location: United States / Providence - 206.130.100.111
List of used Technologies: CSS (Cascading Style Sheets), Html (HyperText Markup Language), Javascript

FortWorthShed.com

Number of used Technologies: 2
Number of used Javascript files: 2
Server Software: Apache/2.2.22 (Ubuntu)
Server Location: United Kingdom / - 176.74.176.187
List of used Technologies: Javascript, Php (Hypertext Preprocessor)

Wasserij en droogkuis uit Oudenbrug

WS Wij wassen en strijken voor particulieren en bedrijven

Number of used Technologies: 10
Number of used Javascript files: 10
Server Software: Apache/2.2.15 (Red Hat)
Server Location: Belgium / - 212.221.60.180
List of used Technologies: DoubleClick.Net, CSS (Cascading Style Sheets), Google Font API, Html (HyperText Markup Language), Html5, Iframe, Javascript, Facebook Box, Google +1 Button

MARIO DIAS, PIANISTA

Number of used Technologies: 2
Number of used Javascript files: 2
Server Software: nginx
Server Location: Czech Republic / - 82.208.18.31
List of used Technologies: Google Analytics, CSS (Cascading Style Sheets), Html (HyperText Markup Language), Html5, Javascript

The Collection - Inhalatorium

Number of used Technologies: 11
Number of used Javascript files: 11
Server Software: Apache/1.3.41 (Unix) mod_gzip/1.3.26.1a mod_layout/3.4 DAV/1.0.3 FrontPage/5.0.2.2635
Server Location: United States / Dallas - 67.228.0.96
List of used Technologies: Wordpress CMS, Google Analytics, CSS (Cascading Style Sheets), Font Awesome, Google Font API, Html (HyperText Markup Language), Html5, Javascript, jQuery, jQuery Cookie, jQuery Cycle, Php (Hypertext Preprocessor), Pingback, BootstrapCDN

video:web:live:magic

Number of used Technologies: 11
Number of used Javascript files: 11
Server Software: Apache
Server Location: United States / Culver City - 205.186.179.192
List of used Technologies: Wordpress CMS, CSS (Cascading Style Sheets), Flexslider, Google Font API, Html (HyperText Markup Language), Html5, Iframe, Javascript, jQuery, MediaElement, Php (Hypertext Preprocessor), Pingback, Spin.js

Organize My Space – "Make space for what matters in life"

Number of used Technologies: 7
Number of used Javascript files: 7
Server Software: Apache/2.4.25
Server Location: United States / Scottsdale - 107.180.4.94
List of used Technologies: Wordpress CMS, CSS (Cascading Style Sheets), Font Awesome, Html (HyperText Markup Language), Html5, Javascript, jQuery, Php (Hypertext Preprocessor), Pingback

PQS Piscinas | Brico Centro López | PQS Piscinas Almería

Venta de productos PQS piscinas en Brico Centro López. Una selección de productos de PQS Piscinas con los mejores precios del mercado.

Number of used Technologies: 3
Number of used Javascript files: 3
Server Software: Apache
Server Location: Spain / - 134.0.10.146
List of used Technologies: Google Analytics, CSS (Cascading Style Sheets), Flexslider, Html (HyperText Markup Language), Iframe, Javascript, SuperFish

Eyeonvegfa.org